NEWPORT BEACH, Calif.--(BUSINESS WIRE)--ROTH Capital Partners (“ROTH”), www.roth.com, a full service investment bank focused on serving emerging growth companies and their investors, today announced that Dr. Elemer Piros has rejoined the firm’s healthcare research team, as Managing Director, Senior Research Analyst covering biotechnology. His research coverage is expected to include SMID cap Biotechnology companies across the therapeutic space, with an initial focus on companies developing novel drugs for CNS, hematology, ophthalmology and liver indications.
Prior to joining ROTH, Dr. Piros was a senior biotechnology analyst at Cantor Fitzgerald and ROTH between 2015 and 2019. Previously, Dr. Piros was the interim CEO of eMMUNITY, Inc, an immunotherapy startup company. Prior to the position at eMMUNITY, he was a publishing senior biotechnology analyst at Rodman & Renshaw and Burrill Securities, covering 80 total companies at various points of time, including companies developing products for CNS disorders, inflammation and the diagnosis and treatment of cancer.
Dr. Piros was a buyside biotechnology analyst at Spear, Leeds & Kellogg, a wholly owned subsidiary of Goldman Sachs. From 1990 to 2000, he conducted academic research in the field of neuroscience, focusing on understanding the molecular mechanism of communication in the nervous system.
Dr. Piros was ranked as the #1 Biotechnology analyst by the Wall Street Journal in 2006 and by the Financial Times in 2010, both based on stock portfolio performance.
Jeff Martin, CFA - Director of Research, commented, “ROTH continues to invest in biotechnology research talent to enhance the strength of our Healthcare platform. I’m pleased to welcome back Elemer to our thought-leading biotechnology research team. His strong academic background combined with his biotechnology industry experience will undoubtedly serve our clients well.”
Dr. Piros commented, “I am delighted to rejoin ROTH, a highly regarded investment bank with a strong track record in healthcare. I am very impressed by the quality and depth of the ROTH research portfolio. My goal is to provide a significant contribution by analyzing companies with cutting-edge medical research and translating science and clinical findings to actionable investment recommendations.”
“We are excited to have Elemer back on our healthcare research team,” said Byron Roth, CEO of ROTH. “His addition further demonstrates our unwavering commitment to the life sciences sector. I’m confident that Elemer’s expertise in biotechnology will enhance our ability to continue to build upon our over 10-year track record of success in assisting both companies and investors in the healthcare sector.”
About Roth Capital Partners, LLC:
ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access.
Headquartered in Newport Beach, Calif., ROTH is privately-held and owned by its employees, and maintains offices throughout the U.S. For more information on ROTH, please visit www.roth.com.
